ATE344316T1 - Substanzen zur vorbeugung und behandlung von autoimmunkrankheiten - Google Patents
Substanzen zur vorbeugung und behandlung von autoimmunkrankheitenInfo
- Publication number
- ATE344316T1 ATE344316T1 AT05021001T AT05021001T ATE344316T1 AT E344316 T1 ATE344316 T1 AT E344316T1 AT 05021001 T AT05021001 T AT 05021001T AT 05021001 T AT05021001 T AT 05021001T AT E344316 T1 ATE344316 T1 AT E344316T1
- Authority
- AT
- Austria
- Prior art keywords
- prevention
- substances
- treatment
- autoimmune disease
- autoimmune diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40165202P | 2002-08-06 | 2002-08-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE344316T1 true ATE344316T1 (de) | 2006-11-15 |
Family
ID=32107846
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03808948T ATE386104T1 (de) | 2002-08-06 | 2003-08-06 | Substanzen zur vorbeugung und behandlung von autoimmunkrankheiten |
AT05021002T ATE344317T1 (de) | 2002-08-06 | 2003-08-06 | Substanzen zur vorbeugung und behandlung von autoimmunkrankheiten |
AT05021001T ATE344316T1 (de) | 2002-08-06 | 2003-08-06 | Substanzen zur vorbeugung und behandlung von autoimmunkrankheiten |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03808948T ATE386104T1 (de) | 2002-08-06 | 2003-08-06 | Substanzen zur vorbeugung und behandlung von autoimmunkrankheiten |
AT05021002T ATE344317T1 (de) | 2002-08-06 | 2003-08-06 | Substanzen zur vorbeugung und behandlung von autoimmunkrankheiten |
Country Status (10)
Country | Link |
---|---|
US (3) | US7381711B2 (de) |
EP (3) | EP1626083B1 (de) |
JP (3) | JP4301567B2 (de) |
CN (3) | CN101147807B (de) |
AT (3) | ATE386104T1 (de) |
AU (1) | AU2003296892B2 (de) |
CA (3) | CA2649821C (de) |
DE (3) | DE60309514T2 (de) |
ES (3) | ES2300652T3 (de) |
WO (1) | WO2004034966A2 (de) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2300652T3 (es) * | 2002-08-06 | 2008-06-16 | Loma Linda University | Sustancias para prevenir y tratar enfermedades autoinmunes. |
WO2006047954A1 (fr) * | 2004-11-04 | 2006-05-11 | Ziyi Cheng | Procédé d'obtention et d'application des matières pour la reconnaissance immunologique d'autoantigènes |
US20090191218A1 (en) | 2005-05-11 | 2009-07-30 | Fengchun Li | DNA Vaccines And Methods For The Prevention Of Transplantation Rejection |
EP2058393B1 (de) * | 2005-05-11 | 2010-07-07 | Loma Linda University | Zusammensetzungen und Verfahren zur Prävention und Behandlung von immunvermittelten Entzündungskrankheiten |
EP2069375B1 (de) | 2006-09-28 | 2012-03-28 | Loma Linda University | Durch apoptotische Zellen vermittelte Transfektion von Säugetierzellen mit interferierender RNA |
US8722915B2 (en) | 2010-05-28 | 2014-05-13 | Dow Corning Corporation | Preparation of organohalosilanes |
US8772525B2 (en) | 2010-05-28 | 2014-07-08 | Dow Corning Corporation | Method for preparing a diorganodihalosilane |
US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
CN108117586A (zh) | 2010-08-10 | 2018-06-05 | 洛桑聚合联合学院 | 红细胞结合性治疗剂 |
US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
WO2012033644A1 (en) | 2010-09-08 | 2012-03-15 | Dow Corning Corporation | Method for preparing a trihalosilane |
EP2651954B1 (de) | 2010-12-17 | 2015-09-16 | Dow Corning Corporation | Verfahren zur herstellung eines trihalosilanes |
US11680273B2 (en) | 2011-09-23 | 2023-06-20 | Loma Linda University | Treatment of autoimmune diseases |
EP3760226A1 (de) | 2011-09-23 | 2021-01-06 | Loma Linda University | Bakterienstämme zur expression von methylasegenen und verwendungen davon |
IN2015DN01936A (de) | 2012-08-13 | 2015-08-07 | Dow Corning | |
CN103116030A (zh) * | 2013-01-30 | 2013-05-22 | 山东东兴生物科技股份有限公司 | 一种检测i型糖尿病自身免疫抗体试剂盒及其检测方法 |
EP3068789B1 (de) | 2013-11-12 | 2021-04-07 | Dow Silicones Corporation | Verfahren zur herstellung eines halosilans |
JP6744227B2 (ja) | 2014-02-21 | 2020-08-19 | エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ(ウペエフエル)Ecole Polytechnique Federale de Lausanne (EPFL) | 糖標的化治療剤 |
US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
WO2016099690A1 (en) | 2014-12-18 | 2016-06-23 | Dow Corning Corporation | Method for producing aryl-functional silanes |
WO2018232176A1 (en) | 2017-06-16 | 2018-12-20 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
US11806386B2 (en) | 2017-08-07 | 2023-11-07 | St. Vincent's Institute Of Medical Research | Type I diabetes therapy |
CA3174524A1 (en) * | 2020-03-03 | 2021-09-10 | Aditxt, Inc. | Methods of treating hyperglycemia and suppressing onset of type 1 diabetes |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5700638A (en) * | 1993-08-26 | 1997-12-23 | Washington University | Cell death regulator |
US5691179A (en) * | 1993-08-26 | 1997-11-25 | Washington University | Cell death regulators |
CN1056380C (zh) * | 1998-02-27 | 2000-09-13 | 中科院成都地奥制药公司 | 抑制人体恶性肿瘤生长的反义寡核苷酸 |
US6645490B2 (en) * | 1998-03-02 | 2003-11-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities |
JP2000236100A (ja) * | 1999-02-17 | 2000-08-29 | Sanyo Electric Co Ltd | 半導体素子 |
WO2000059538A2 (en) * | 1999-04-08 | 2000-10-12 | The John Hopkins University | Antigen-specific induction of peripheral immune tolerance |
CN1117098C (zh) * | 1999-06-25 | 2003-08-06 | 北京金赛狮生物制药技术开发有限责任公司 | 针对囊依赖的淋巴细胞白血病基因的反义核酸的抑癌作用 |
ES2300652T3 (es) * | 2002-08-06 | 2008-06-16 | Loma Linda University | Sustancias para prevenir y tratar enfermedades autoinmunes. |
-
2003
- 2003-08-06 ES ES03808948T patent/ES2300652T3/es not_active Expired - Lifetime
- 2003-08-06 AT AT03808948T patent/ATE386104T1/de not_active IP Right Cessation
- 2003-08-06 WO PCT/US2003/024625 patent/WO2004034966A2/en active IP Right Grant
- 2003-08-06 DE DE60309514T patent/DE60309514T2/de not_active Expired - Lifetime
- 2003-08-06 CA CA2649821A patent/CA2649821C/en not_active Expired - Lifetime
- 2003-08-06 DE DE60309513T patent/DE60309513T2/de not_active Expired - Lifetime
- 2003-08-06 CN CN2007100979587A patent/CN101147807B/zh not_active Expired - Fee Related
- 2003-08-06 AT AT05021002T patent/ATE344317T1/de not_active IP Right Cessation
- 2003-08-06 EP EP05021002A patent/EP1626083B1/de not_active Expired - Lifetime
- 2003-08-06 US US10/523,655 patent/US7381711B2/en active Active
- 2003-08-06 AU AU2003296892A patent/AU2003296892B2/en not_active Expired
- 2003-08-06 CA CA2653201A patent/CA2653201C/en not_active Expired - Lifetime
- 2003-08-06 ES ES05021001T patent/ES2275253T3/es not_active Expired - Lifetime
- 2003-08-06 EP EP03808948A patent/EP1543109B1/de not_active Expired - Lifetime
- 2003-08-06 CN CNB038190087A patent/CN100389192C/zh not_active Expired - Fee Related
- 2003-08-06 DE DE60319103T patent/DE60319103T2/de not_active Expired - Lifetime
- 2003-08-06 CA CA002494888A patent/CA2494888C/en not_active Expired - Lifetime
- 2003-08-06 EP EP05021001A patent/EP1624053B1/de not_active Expired - Lifetime
- 2003-08-06 ES ES05021002T patent/ES2275254T3/es not_active Expired - Lifetime
- 2003-08-06 JP JP2004545230A patent/JP4301567B2/ja not_active Expired - Fee Related
- 2003-08-06 CN CN2007100979572A patent/CN101057976B/zh not_active Expired - Fee Related
- 2003-08-06 AT AT05021001T patent/ATE344316T1/de not_active IP Right Cessation
-
2007
- 2007-08-09 US US11/836,661 patent/US7638498B2/en not_active Expired - Lifetime
- 2007-08-09 US US11/836,640 patent/US20080171713A1/en not_active Abandoned
-
2009
- 2009-02-06 JP JP2009025647A patent/JP5555431B2/ja not_active Expired - Fee Related
- 2009-02-06 JP JP2009025648A patent/JP5123226B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE344316T1 (de) | Substanzen zur vorbeugung und behandlung von autoimmunkrankheiten | |
DE602004010407D1 (de) | Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden | |
DE602004021797D1 (de) | Behandlung von alzheimer-krankheit und amyloider gehirnangiopathie | |
ATE422358T1 (de) | Kombinationstherapie mittels reovirus und anti- antireovirus antikörpern zur behandlung von ras- vermittelten, proliferativen erkrankungen | |
ATE472325T1 (de) | Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen | |
DE602004028763D1 (de) | Te zur behandlung von virenerkrankungen | |
ATE251903T1 (de) | Verwendung von phosphororganischen verbindungen zur therapeutischen und prophylaktischen behandlung von infektionen | |
ATE527375T1 (de) | Diagnose und behandlung von brustkrebs mit scn5a | |
ATE457166T1 (de) | Orale zusammensetzungen zur behandlung von diabetes | |
ATE542801T1 (de) | Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine | |
ATE468137T1 (de) | Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten | |
DE60221665D1 (de) | Impfstoff zur verhütung und behanldung von alzheimer-demenz und von amyloid-bezogenen krankheiten | |
IS2925B (is) | Ákvörðun á batahorfum sjúklings sem undirgengst meðhöndlun við Alzheimer-sjúkdómi | |
DE602004017658D1 (de) | Zur Behandlung von Schmerzen geeignete therapeutische Mittel | |
ATE527022T1 (de) | Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie | |
DE69718150T2 (de) | Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien | |
EA200500098A1 (ru) | Лекарственное средство и способ лечения патологического синдрома | |
ATE514430T1 (de) | Behandlung des alpha-galactosidase a mangels | |
DE69703689D1 (de) | Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia | |
ATE381347T1 (de) | Kombinationen von ezetimibe und aspirin zur behandlung von kardiovaskulären erkrankungen | |
DE60204466D1 (de) | Integrinhemmer zur behandlung von augenkrankheiten | |
DE60027209D1 (de) | Arzneimittel enthaltend hydroxyapatite zur behandlung von knochengewebserkrankungen | |
ATE357912T1 (de) | Intrakorporelle medikamente zur hoch- energetischen phototherapeutischen behandlung von krankheiten | |
DE60224004D1 (de) | Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten | |
DE69829217D1 (de) | Vorrichtung zur therapeutischen behandlung von blutgefässen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |